Analytical Data
-
基因名
DNGR-1/CLEC9A
-
简介
The CLEC9A protein is uniquely expressed on specific myeloid cells and acts as an endocytic receptor responsible for the uptake and processing of materials from dead cells. CLEC9A recognizes filamentous actin, especially in damaged cell membranes, and plays a critical role in Syk-dependent cross-presentation of dead cell antigens. CLEC9A Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CLEC9A protein, expressed by HEK293 , with N-hFc labeled tag.
- Application
-
别名
C-type lectin domain family 9 member A; CD370; Dngr-1
-
种属
Mouse
-
表达系统
HEK293
-
标签
N-hFc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8BRU4-4
-
表达区间
K57-I264
-
蛋白长度
Extracellular Domain
-
分子量
52.1 kDa.
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DNGR-1, also known as CLEC9A (C-type lectin domain family 9 member A), is a receptor predominantly expressed on dendritic cells, playing a crucial role in the immune response. It is involved in recognizing necrotic cells and certain pathogens, thus activating dendritic cells to initiate adaptive immunity. Research has highlighted DNGR-1's potential as a target for therapeutic strategies in cancer and infectious diseases due to its ability to enhance T-cell activation and promote robust immune responses. The development of recombinant DNGR-1/CLEC9A proteins has enabled researchers to better understand its structure-function relationship, signaling pathways, and interactions with ligands. Such studies aim to elucidate how DNGR-1 can be harnessed in vaccine development or immunotherapy, offering promising avenues for treating various diseases. Furthermore, the exploration of DNGR-1's role in modulating immune responses has significant implications for improving treatment outcomes in immunotherapy, especially in designing strategies that leverage the body's own immune system to combat tumors and chronic infections.
